# Identifying and Targeting Mechanisms for Membrane Signaling in Human Cancer

> **NIH NIH R01** · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2024 · $526,562

## Abstract

PROJECT SUMMARY
Lung cancer is the leading cause of cancer deaths worldwide. The most prevalent type of lung cancer is Non-
Small Cell Lung Cancer (NSCLC). Within NSCLC, the most common subtype is adenocarcinoma (LUAD). The
goal of this application is to implement a collaborative effort involving two PIs with complimentary expertise in
preclinical models, proteomics and functional genomics to understand the role of RhoA and RAP1GDS1 in
driving oncogenic KRAS in LUAD Our extensive preliminary data indicates that blockade of combined loss of
RhoA and RAP1GDS1 leads to decreased proliferation and increased apoptosis in a KRAS-dependent
manner. The Sweet-Cordero and Jackson laboratories have collaborated intensively over the past several
years first to identify this synthetic vulnerability and second to understand the mechanistic basis underlying it.
In Aim 1, we will use functional and cell biology approaches to define the role of RAP1GDS1 in cell
proliferation and growth in 3D. We will also expand our studies to evaluate the role of other Rho proteins as
interactors with RAP1GDS1. In Aim 2, we will use proteomic approaches to further elucidate the
consequences of RAP1GDS1 loss and specifically the differences between the long and short isoforms of this
protein in the regulation of cell signaling. Finally, in Aim 3, we propose a series of experiments involving both
PDX models of LUAD and GEM models of LUAD to further elucidate the genotype specificity of the interaction
between RAP1GDS1 and RhoA. We will also explore the potential therapeutic implications of this combined
vulnerability using Rock inhibitors and inhibition of RAP1GDS1 interaction with key downstream proteins.

## Key facts

- **NIH application ID:** 10745929
- **Project number:** 5R01CA250534-04
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- **Principal Investigator:** PETER Kent JACKSON
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $526,562
- **Award type:** 5
- **Project period:** 2020-12-10 → 2025-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10745929

## Citation

> US National Institutes of Health, RePORTER application 10745929, Identifying and Targeting Mechanisms for Membrane Signaling in Human Cancer (5R01CA250534-04). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10745929. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*